The government announced that the UK and US have agreed a new pharmaceutical deal that establishes a preferential tariff framework for medicinal products, making the UK the only country to secure a 0% tariff on pharmaceutical exports to the US. Under the terms of the agreement, this preferential 0% tariff rate will apply for at least three years. The deal will also secure preferential terms for the UK’s medtech exports, meaning no additional new tariffs on medtech, which the government states is intended to unlock further investment and support additional growth. The Department of Health and Social Care (DHSC) has stated that the UK-US pharmaceuticals deal will help secure access to medicines for NHS patients and accelerate the arrival of new therapies. The government also intends to raise the thresholds used by NICE (from £20,000–£30,000 to £25,000–£35,000 per quality-adjusted life year (QALY)), aligning with commitments linked to the deal.